Compare Inovio Pharmaceuticals Inc (INO) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Manulife Financial Corporation trades at $42.51 (market cap $69.96B). The key difference: Manulife Financial Corporation is far larger — about 783.7× Inovio Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.14% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MFC | |
|---|---|---|
Market Cap | $89.27M | $69.96B |
Sector | Health | Financials |
52-Week High | $2.87 | $43.39 |
52-Week Low | $1.05 | $29.90 |
Enterprise Value | $60.28M | $66.52B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
MFC trades at $42.83, down 1.29% today, with a bullish technical signal supported by moving averages. The company reported revenue of $53.01B in 2025 and net income of $5.78B, with a P/E of 17.39. Recent news highlights AI advancements and strong Asia performance, while Q1 2026 earnings missed expectations. Analyst consensus is 57% buy with no sell ratings.
Outlook remains positive driven by AI initiatives and Asia growth, but risks include Q1 earnings miss and regulatory scrutiny. The stock offers steady profitability and dividend income, yet faces headwinds from wealth management outflows and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
